Akt, when activated by IGF/insulin, can phosphorylate forkhead transcription factors. We undertook this study to determine whether epidermal growth factor (EGF) treatment could produce a signaling cascade resulting in phosphorylation of the forkhead transcription factor FKHR in a breast cancer cell line, MDA-MB-231. After establishing ErbB1, cbl, PI3 kinase and Akt were activated in EGF treated MDA-MB-231, we determined by immunoblot with FKHR antiserum that the electrophoretic mobility of FKHR was retarded after EGF treatment. This mobility retardation was reversible by treatment with alkaline phosphatase, and immunoblot with phospho-Ser 256 FKHR antibody further con®rmed phosphorylation on an Akt consensus site after EGF treatment. EGF stimulated FKHR phosphorylation was blocked by the PI3 kinase inhibitor LY294002, and the ErbB1 inhibitor AG1478. FKHR immunoblotting after puri®cation of nuclear and cytoplasmic proteins showed that EGF induced a simultaneous increase of FKHR in the cytoplasm and decrease in the nucleus. This ®nding was con®rmed by immuno¯uorescence staining. Treatment of cells with pharmacological inhibitors of PI3 kinase or ErbB1 blocked this eect. Thus, these results demonstrate the phosphorylation and nuclear exclusion of FKHR after EGF treatment by a PI3 kinase dependent mechanism, and represent the ®rst report of growth factor regulation of endogenous FKHR localization Oncogene (2000) 19, 4574 ± 4581.
Introduction
The four ErbB family members (ErbB1, or EGFR; ErbB2 or Her2 or neu; ErbB3 or Her3; ErbB4 or Her4) are critical regulators of tumorigenesis (Salomon et al., 1995) . They exert eects by the activation of speci®c signal transduction cascades after exposure to various ligands such as heregulin and EGF family members EGF and transforming growth factor (TGF)a. Two of these cascades implicated in tumorigenesis are the mitogen activated protein (MAP) kinase and PI3 kinase pathways. Immediately following ligand binding, ErbB receptors from hetero and homo dimers thereby activating the intrinsic kinase activity of the receptor which leads to autophosphorylation of speci®c C terminal tyrosine residues. These phosphorylated residues couple to downstream src homology-2 (SH2) and phosphotyrosine binding (PTB) domain containing signaling molecules such as PLCg, Shc, cbl and PI3 kinase (Hackel et al., 1999) . Activation of the grb2/sos, ras, raf, MEKK, MAP kinase pathway, which leads to cell proliferation, survival and cell motility, can occur directly through ErbB1 (Gale et al., 1993; Li et al,. 1993) or through Shc (Thomas and Bradshaw, 1997; Vijapurkar et al., 1998) . Activation of the PI3 kinase pathway by EGF has been shown to occur most eciently by two mechanisms. Ligand induced activation of ErbB1 leads to phosphorylation of the kinase de®cient ErbB3, either directly or laterally through ErbB2 (Graus-Porta et al., 1997) . ErbB3 contains ®ve C-terminal sites in the p85 binding motif, which, when phosphorylated, recruit and activate p85 PI3 kinase (Solto et al., 1994) . In cells lacking ErbB3, EGF signals to PI3 kinase through the molecule cbl (Solto and Cantley, 1996) , which contains two tyrosine residues in the YXXM p85 binding motif (Cantley et al., 1991) . Like ErbB3, cbl is phosphorylated on these tyrosine residues, leading to p85 binding and PI3 kinase activation. ErbB1, ErbB2 and ErbB4 bind p85 weakly in their C terminus and therefore must employ ErbB3 or cbl to eciently signal to PI3 kinase (Hu et al., 1992; Solto et al., 1994) .
After PI3 kinase is activated, PtdIns-4,5-P2 is converted to PtdIns-3,4,5-P3 which can then bind the pleckstrin homology (PH) domain of Akt (Stephens et al., 1998) . This binding has two results: it facilitates Akt translocation to the plasma membrane and it exposes key serine/threonine residues to phosphorylation by PDKs (Downward, 1998a ). The activated Akt can then phosphorylate substrates such as BAD (Datta et al., 1997) and Caspase 9 (Cardone et al., 1998) . Activated Akt also translocates to the nucleus Meier et al., 1997) where, as recently discovered, it can phosphorylate the forkhead family transcription factors (Brunet et al., 1999; Guo et al., 1999; Kops et al., 1999; Nakae et al., 1999; Rena et al., 1999; Tang et al., 1999) .
Recent transfection studies have demonstrated the phosphorylation of three forkhead family members by Akt in mammalian cells: FKHRL1 (Brunet et al., 1999) FKHR Tang et al., 1999) and AFX (Kops et al., 1999) . Un-phosphorylated forkhead transcription factors reside in the nucleus, where they are bound to insulin response elements in the insulinlike growth factor BP-1, PEPCK and TAT (Durham et al., 1999; Guo et al., 1999) genes, and to the Fas ligand promoter (Brunet et al., 1999) . Following phosphorylation by Akt, forkhead family members have been shown to translocate from the nucleus to the cytoplasm by an active export mechanism involving Crm1 (Biggs et al., 1999) , where they are sequestered by 14-3-3 protein (Brunet et al., 1999) . This phosphorylation and subsequent cytoplasmic localization has been shown to have an anti-apoptotic eect (Brunet et al., 1999; Tang et al., 1999) . While each of these studies has helped to elucidate the mechanisms of action of the forkhead family, they have been limited in several ways. For example, these studies were largely restricted to transfection experiments, thus generating little data for endogenous forkhead. Additionally, data for phosphorylation of forkhead has been limited to serum, IGF-I/insulin or constitutively active Akt. We therefore undertook this study to investigate EGF signal transduction and regulation of endogenous FKHR. We found that EGF stimulation of MDA-MB-231 cells resulted in activation of all pathways necessary for phosphorylation of FKHR: ErbB1, cbl, PI3 kinase and Akt. EGF also caused an electrophoretic mobility retardation of FKHR as determined by immunoblot. This mobility shift was reversible by treatment with alkaline phosphatase, and was blocked by the PI3 kinase inhibitor LY294002, or with the ErbB1 inhibitor AG1478. Phosphorylation of FKHR on one consensus Akt phosphorylation site was con®rmed by phospho-Ser 256 FKHR immunoblot. The phosphorylation of FKHR was correlated with an increase of cytoplasmic FKHR and decrease of nuclear FKHR. Thus, these data demonstrate that endogenous FKHR is phosphorylated and translocates from the nucleus to the cytoplasm after EGF treatment by a PI3 kinase dependent pathway.
Results

Phosphorylation of FKHR after EGF treatment in MDA-MB-231 cells
We ®rst established the pathways utilized by MDA-MB-231 after EGF treatment. Consistent with previous ®ndings (Lewis et al., 1996) , we found after immunoprecipitation with speci®c antibodies that ErbB1 and ErbB2, but not ErbB3 were tyrosine phosphorylated at 1 and 10 min after EGF treatment (data not shown). The adaptor molecule cbl was tyrosine phosphorylated and associated with ErbB1 after EGF treatment, and PI3 kinase activity was increased after EGF treatment in cbl immunoprecipitates (data not shown). Thus, EGF activated ErbB1, which led to activation of cbl, a well-known modulator of PI3 kinase. Akt was also activated after EGF treatment (data not shown and Figure 3 ). Our data, taken with previous ®ndings, con®rm that MDA-MB-231 cells have all the necessary components for activation of the transcription factor FKHR.
It has been previously shown that after phosphorylation by Akt, FKHR undergoes an electrophoretic mobility retardation. To determine if FKHR was phosphorylated after EGF treatment in MDA-MB-231 cells, we separated lysates by SDS ± PAGE using a low ratio of crosslinker in the gel to better resolve phospho species. We found after EGF treatment that antiserum to FKHR recognized an increase in higher molecular weight bands (Figure 1 , lane 3 versus lane 1, indicated by bracket) and a simultaneous decrease in intensity of the lowest molecular weight band ( Figure  1 , lane 3 versus lane 1, indicated by arrow). This eect was maximal at 10 min (Figure 1, lane 3) , while some slower migrating bands were still present after 3 h, however at this time point most FKHR was again contained in the lower band (Figure 1, lane 6) . These results are consistent with the reported mobility retardation of FKHRL1 after activation by constitutively active Akt or IGF-1 and FKHR after insulin treatment (Brunet et al., 1999; Nakae et al., 1999; Tang et al., 1999) .
After observing an apparent mobility shift of FKHR in EGF treated cells, we next sought to con®rm this eect was due to a phosphorylation event. We treated lysates of EGF stimulated cells with alkaline phosphatase, then immunoblotted with FKHR antiserum. We found that the slower migrating bands of FKHR present after EGF treatment ( Figure 2a , lane 2) could be abrogated by treatment with alkaline phosphatase (Figure 2a, lane 3) . This dephosphorylation was characterized by a simultaneous decrease in the higher molecular weight bands (Figure 2a , indicated by bracket) and increase in intensity of the lowest molecular weight band (Figure 2a , indicated by arrow). These data, taken with previous reports of FKHR mobility retardation, indicate the slower migrating FKHR bands observed in EGF treated cells were due to phosphorylation. Of note is the presence of a band migrating just above the arrow in all three lanes. Alkaline phosphatase treatment did not diminish this band suggesting it may not represent a phosphospecies.
To further verify FKHR phosphorylation, we performed an immunoblot in standard SDS ± PAGE with an antibody speci®c to phosphorylated Ser 256 residue of FKHR, a residue known to be a substrate for Akt. We found an increase in phospho-Ser 
EGF stimulated FKHR phosphorylation is blocked by inhibitors of PI3 kinase and ErbB1
To determine whether EGF treatment caused phosphorylation of FKHR by a PI3 kinase dependent manner, we pretreated cells either with the PI3 kinase inhibitor LY294002, or the ErbB1 inhibitor AG1478 and then stimulated with EGF. After SDS ± PAGE using low crosslinker ratio, we found that cells treated with DMSO alone, then EGF stimulated, had the characteristic mobility retardation of FKHR ( To con®rm results observed in Figure 3a , we stimulated cells with EGF and separated lysates in standard 10% SDS ± PAGE, followed by immunoblot with phospho- After treatment, cells were stimulated with 50 ng/ml EGF for 10 min, lysed in 26 Laemmli sample buer, separated by standard 10% SDS ± PAGE (29 : 1 acrylamide:bis/acrylamide) and immunoblotted with phospho-Ser 256 FKHR antibody, followed by FKHR immunoblot. (c) Serum starved 70% con¯uent MDA-MB-231 monolayers were treated for 30 min with DMSO or 5 mM AG1478 and then stimulated for 10 min with 50 ng/ml EGF. After lysis, equal amounts of protein were immunoprecipitated with ErbB1 antibody and then separated by standard SDS ± PAGE and antiphosphotyrosine immunoblotted. (d) Serum starved 70% con¯uent MDA-MB-231 monolayers were treated for 30 min with DMSO, 25 mM LY294002 or 5 mM AG1478, stimulated with 50 ng/ml EGF for 1 min as indicated and lysed. Equal amounts of protein were immunoprecipitated with cbl antibody and a PI3 kinase assay was performed according to Materials and methods. All data shown are representative of two independent experiments Figure 3c shows that pretreatment with the ErbB1 inhibitor AG1478 completely abolished ErbB1 activation after EGF treatment. Figure 3d shows that PI3 kinase activity was appropriately inhibited by LY294002 and AG1478 (*50% and *90% reduction, respectively, as determined by densitometry analysis). Taken together, these data indicate that the EGF induced phosphorylation of FKHR was PI3 kinase dependent, and ErbB1 speci®c.
EGF promotes nuclear exclusion of FKHR by a PI3 kinase and ErbB1 dependent mechanism
Others have shown that transfected forkhead family members translocate from the nucleus to the cytoplasm after insulin/IGF-I or serum treatment (Biggs et al., 1999; Brunet et al., 1999; del Peso et al., 1999; Takaishi et al., 1999) . To determine if EGF could promote translocation of endogenous FKHR, we stimulated cells for 0, 10 or 30 min, then puri®ed nuclear and cytoplasmic proteins. In order to quantitate total FKHR levels, protein was resolved by standard 10% SDS ± PAGE so that all phospho species of FKHR would migrate as a single band. Figure 4a , upper panel, shows that after EGF treatment, FKHR levels increased in the cytoplasm, and decreased in the nucleus. This eect was maximal at 10 min (approximately 50 ± 60% translocation), and began to diminish after 30 min of EGF treatment. Densitometric analysis of FKHR levels is represented graphically, FKHR levels in total cellular extract were unchanged after EGF treatment (Figure 4a, upper panel) . These data correlate with the mobility retardation observed in Figure 1 : the amount of phosphorylated FKHR (approximately 50% of the total FKHR) was maximal at 10 min of EGF treatment, and subsequently diminished by 30 min. Further immunoblotting con®rmed the cytoplasmic protein IRS-1 was contained mostly in the cytoplasmic fraction, while the nuclear protein c-Jun was contained mostly in the nuclear fraction, both were found in the total cellular extract (Figure 4a , bottom panels).
To verify this nuclear to cytoplasmic translocation, we performed immuno¯uorescence staining with FKHR antiserum after SFM alone or EGF treatment for 10 min. In SFM alone treated cells, we observed mostly nuclear and diuse cytoplasmic staining ( Figure  4b , left panel, indicated by arrows). After EGF treatment for 10 min, we found predominately diuse cytoplasmic staining, with approximately 60% of cells showing no nuclear staining (Figure 4b , right panel, indicated by arrows). These ®ndings were consistent with the results in Figure 4a . Staining cells with secondary antibody alone produced a weak, generally cytoplasmic staining that was unchanged by EGF treatment (data not shown).
In order to show that the nuclear to cytoplasmic translocation of FKHR was PI3 kinase dependent and ErbB1 speci®c, cells were treated with inhibitors and stimulated as in Figure 3 . Nuclear and cytoplasmic proteins were puri®ed and resolved as in Figure 4a . We again found that after EGF stimulation, FKHR levels increased in the cytoplasm ( Densitometric analysis of these data is represented graphically. Further immunoblotting again showed that the cytoplasmic protein IRS-1 was contained mostly in the cytoplasmic fraction, while the nuclear protein c-Jun was contained mostly in the nuclear fraction ( Figure 5 , lower panels).
Discussion
Growth factor tyrosine kinase receptors are important regulators of cancer cell proliferation and survival. These signals are transduced by the activation of a complex series of adapter molecules and kinases. One monolayers were stimulated with 50 ng/ml EGF for 0, 10 or 30 min, then nuclear and cytoplasmic proteins, and a total protein extract, were puri®ed and resolved by standard 10% SDS ± PAGE (29 : 1 acrylamide:bis/acrylamide) according to Materials and methods. After FKHR immunoblot, densitometry analysis was performed and is shown graphically. IRS-1 and c-Jun immunoblots were performed as controls for cytoplasmic and nuclear puri®cations, respectively (lower panels). Molecular weight markers are noted at the right. These data are representative of two independent experiments. (b) Serum starved 70% con¯uent MDA-MB-231 monolayers were stimulated with 50 ng/ml EGF or SFM alone for 10 min, the cells were ®xed, stained with FKHR antibody followed by¯uorescein-conjugated donkey antirabbit secondary antibody, and photographed as described in Materials and methods. Shown are representative ®elds of view from SFM alone and EGF treated cells. Arrows indicate diuse nuclear/cytoplasmic staining in SFM treated cells, while in EGF treated cells, staining was con®ned predominately to the cytoplasm, also indicated by arrows of the most important molecules involved in signaling for EGF, TGFa, insulin/IGF-I, platelet derived growth factor, interleukins and numerous other cytokines and growth factors is PI3 kinase (Wymann and Pirola, 1998). It is composed of two subunits: an 85 kDa regulatory subunit, and a 110 kDa catalytic subunit. After activation by a tyrosine kinase, PI3 kinase converts PtdIns-4,5-P2 to PtdIns-3,4,5-P3, which then has several functions, one of which is binding the PH domain of the serine/threonine kinase Akt. After PtdIns-3,4,5-P3 binding, Akt translocates to the plasma membrane where key serine/threonine residues are phosphorylated by PDKs (Downward, 1998b) . Transfection studies have shown that Akt, after being activated by IGF-I/insulin in this manner, can phosphorylate members of the forkhead family transcription factors (Brunet et al., 1999; Guo et al., 1999; Kops et al., 1999; Nakae et al., 1999; Rena et al., 1999; Tang et al., 1999) .
The impetus for linking Akt to forkhead came from recent genetic studies in Caenorhabditis elegans. When larvae are grown in sub-optimal conditions, they arrest developmentally and metabolically in a dauer stage. The dauer stage can also be induced by mutations in the IGF/insulin receptor homolog (daf-2) (Kimura et al., 1997) , the PI3 kinase homolog (age-1) (Morris et al., 1996) or Akt homologs (akt-1 and akt-2) (Paradis and Ruvkun, 1998). However, if the forkhead homolog daf-16 is mutated, mutations to IGF/insulin receptor, PI3 kinase or Akt homolog do not cause a dauer stage, suggesting the forkhead homolog daf-16 is antagonized by the IGF/insulin-PI3 kinase-Akt pathway (Ogg et al., 1997) . These interactions were con®rmed in mammalian cells in a series of transfection experiments using the three daf-16 human homologs: FKHR, FKHRL1 and AFX.
Studies presented here show that EGF caused phosphorylation of endogenous levels of the forkhead family member FKHR. Phosphorylation was initially shown by detection of a mobility shift in FKHR after EGF treatment. IGF/insulin and constitutively active Akt also cause a similar mobility shift, shown to be phosphorylation, in several other systems (Brunet et al., 1999; Nakae et al., 1999; Tang et al., 1999) . Further evidence that the observation of slower migrating bands was due to phosphorylation was the reversible nature of these slower migrating bands by alkaline phosphatase. One band recognized by FKHR antiserum was resistant to alkaline phosphatase treatment, suggesting its presence was not due to phosphorylation of FKHR. It is possible this band represents another isoform of FKHR, or, perhaps, a post-translational modi®cation of FKHR other than phosphorylation.
Immunoblotting with a phospho- (Brunet et al., 1999; Tang et al., 1999) , while others have concluded only Ser 256 is required for forkhead regulation Nakae et al., 1999) . It has just recently been shown that Ser 256 FKHR may act as à gate keeper' phosphorylation site, where its phosphorylation by Akt is necessary to permit phosphorylation of Thr 24 and Ser 319 (Nakae et al., 2000) . The phosphorylation of FKHR in MDA-MB-231 cells was correlated with its translocation from the nucleus to the cytoplasm. This phenomenon has been observed for forkhead family members after serum treatment in other systems, however, these studies required transfection to show this eect (Biggs et al., 1999; Brunet et al., 1999; Takaishi et al., 1999) . The data shown here demonstrate endogenous FKHR translocates from the nucleus to the cytoplasm after EGF treatment. The degree of phosphorylation of FKHR directly correlated with its subcellular localization. At 10 min of EGF stimulation, FKHR phosphorylation was maximal, while protein levels in the nucleus were minimal. Immuno¯uorescence staining con®rmed this eect. By 30 min, phosphorylation began to diminish, and levels again increased in the nucleus. Furthermore, when PI3 kinase activity was partially blocked by LY294002, phosphorylation of Akt and FKHR was blocked, and FKHR levels were unchanged in the nucleus and cytoplasm after EGF treatment. The *50% reduction in EGF stimulated PI3 kinase activity observed after LY294002 treatment was similar to inhibition of PI3 kinase activity using wortmannin in other cancer cells (Jackson et al., 1998) . The ErbB1 inhibitor AG1478, which competes for ATP binding in the kinase domain of ErbB1, completely abolished ErbB1 tyrosine phosphorylation as well as all downstream signaling: PI3 kinase, Akt, FKHR phosphorylation and nuclear exclusion. EGF stimulated nuclear exclusion of FKHR is blocked by PI3 kinase and ErbB1 inhibitors. Serum starved 70% con¯uent MDA-MB-231 monolayers were treated for 30 min with DMSO, 25 mM LY294002 or 5 mM AG1478 as indicated. After treatment, cells were stimulated with 50 ng/ml EGF for 10 min, then nuclear and cytoplasmic proteins were puri®ed and resolved by standard 10% SDS ± PAGE (29 : 1 acrylamide:bis/acrylamide) according to Materials and methods. After FKHR immunoblot, densitometry analysis was performed and is shown graphically. IRS-1 and cJun immunoblots were performed as controls for cytoplasmic and nuclear puri®cations, respectively (lower panels). Molecular weight markers are noted at the right. These data are representative of two independent experiments
The signaling events we found in MDA-MB-231, taken with other studies, suggest a direct mechanism for phosphorylation of FKHR by EGF: ErbB1 bound EGF and formed homodimers and/or heterodimers with ErbB2, cbl associated (directly or indirectly) with the activated ErbB1, PI3 kinase activity was associated with cbl, Akt was activated, FKHR was phosphorylated on an Akt consensus site and FKHR translocated from the nucleus to the cytoplasm. Because we did not use transfection to demonstrate these signaling events, we cannot conclude that FKHR was a direct substrate for Akt. As noted in a previous publication, it is possible other kinases could be involved in phosphorylation of FKHR in vivo (Brunet et al., 1999) .
We have shown here that EGF can produce a signaling cascade that results in the phosphorylation of FKHR. Furthermore, this phosphorylation is correlated with the nuclear to cytoplasmic translocation of FKHR. These data represent the ®rst report of regulation of an endogenous forkhead transcription factor by a growth factor, all other studies having been performed using ectopically expressed Forkhead family members. Furthermore, to our knowledge, these data provide the ®rst evidence linking the ErbB family of receptors to the forkhead family of transcription factors, as well as the ®rst report of FKHR regulation in a breast cancer cell line.
Materials and methods
Reagents
All chemicals and reagents were purchased from Sigma (St. Louis, MO, USA) unless noted otherwise. p85 PI3 kinase antibody was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Total and phospho-speci®c (activated) Akt, and phospho-Ser 256 FKHR antibodies were purchased from New England Biolabs (Beverly, MA, USA). c-Jun, ErbB1, ErbB2 and ErbB3 antibodies were from Santa Cruz Biotech (Santa Cruz, CA, USA). cbl PY-20 and RC-20 antiphosphotyrosine were purchased from Transduction Labs (Lexington, KY, USA),¯uorescein-conjugated donkey antirabbit antibody and horse radish peroxidase (HRP) linked anti-rabbit antibody were from Jackson Immunoresearch (West Grove, PA, USA). FKHR antiserum (Durham et al., 1999) and IRS-1 antiserum have been described. LY294002 and AG1478 were from Calbiochem (LaJolla, CA, USA). Molecular weight markers and protein A agarose were from Gibco BRL (Bethesda, MD, USA). Acrylamide and bis/acrylamide were from BioRad (Hercules, CA, USA). MDA-MB-231 cells were originally from American Type Culture Collection (Rockville, MD, USA).
Cell stimulation and lysis
Cells were grown to 70% con¯uency in DMEM with 5% fetal calf serum, then starved overnight in serum-free medium (SFM, DMEM with penicillin/streptomycin and L-Glutamine). For treatment with LY294002 or AG1478, cells were pre-incubated for 30 ± 60 min with DMSO, or drugs at indicated concentrations in DMSO. Final concentration of drug/DMSO or DMSO in the medium was 0.6%. Fifty ng/ml EGF was then added for indicated times. For other experiments, medium was replaced with SFM+50 ng/ml EGF as indicated. Cells were washed twice in ice cold PBS and lysed with 500 ml per 10 cm plate with TNESV buer (50 mM Tris pH 7.4, 1% NP-40, 2 mM EDTA, 100 mM NaCl, 10 mM sodium orthovanate, 1 complete protease inhibitor cocktail tablet [Boehringer Mannheim, Mannheim, Germany] per 10 mls lysis buer). Protein concentration of the cleared lysates was determined by the copper-bicinchoninic acid method with a Pierce Laboratory kit (Rockford, IL, USA). For phopsho-Ser 256 FKHR immunoblot, cell monolayers were lysed in 26 Laemmli sample buer, according to manufacturer's instructions (New England Biolabs).
Alkaline phosphatase treatment
Cells were grown, stimulated and washed as above. Cells were lysed in 50 mM Tris pH 7.4, 137 mM NaCl, 1% NP-40. After protein concentration was determined as above, 50 mg of cellular protein was treated with 5 units of calf intestinal alkaline phosphatase (Promega, Madison, WI, USA) in 50 ml of 50 mM Tris, 1 mM MgCl, with 106 alkaline phosphatase buer, for 30 min at 308C. Reaction was stopped by addition of 26 Laemmli loading buer and boiling for 5 min before SDS ± PAGE.
Immunoblotting
After SDS ± PAGE (low crosslinker ratio of 30 : 0.4 acrylamide:bis/acrylamide for FKHR blots in Figures 1, 2a and 3a; standard ratio of 29 : 1 acrylamide:bis/acrylamide for all other blots) proteins were transferred overnight to nitrocellulose membranes (Amersham Pharmacia Biotech, Arlington Heights, IL, USA). All blotting steps were carried out at room temperature with gentle rocking. The membranes were blocked in 5% non-fat dry milk in Tris-buered salinetween 20 (TBST-0.15 M NaCl, 0.01 M Tris HCl pH 7.4, 0.05% tween 20). Phospho-Ser 256 FKHR antibody incubation was overnight in 5% BSA. All other blots were incubated with a 1000 : 1 dilution of indicated antibody in blocking buer for 1 h. After washing, blots were then incubated with a 2000 : 1 dilution of horseradish peroxidase linked secondary antibody in blocking buer for 1 h, followed by further washing. Enhanced chemiluminescence was performed according to manufacturer's instructions (Amersham Pharmacia Biotech, Arlington Heights, IL, USA). Immunoprecipitations were performed as previously described (Jackson et al., 2000) .
PI3 kinase assay
After growth factor treatment, 70% con¯uent cell monolayers were washed, lysed and equal amounts of protein were incubated with primary antibody for 30 min followed by further incubation with protein A agarose was for 2 h. Immunocomplexes were washed twice each in PBS, 1% Nonidet P40; 100 mM Tris, 5 mM LiCl; 10 mM Tris, 150 mM NaCl, 5 mM EDTA; all buers included 10 mM sodium orthovanadate. After the last wash was removed, a PI3 kinase assay was performed as previously described (Jackson et al., 1998) . Brie¯y, samples were resuspended in 50 ml of PI3 kinase buer (20 mM Tris, pH 7.5; 100 mM NaCl; 0.5 mM EGTA) and 10 mg of phosphatidylinositol was added. After 10 min at room temperature, 10 mCi of [ 32 P]ATP and MgCl 2 to a ®nal concentration of 20 mM was added. After 10 min at room temperature, lipids were extracted. First with 150 ml of CHCl 3 :MeOH:HCl (10 : 20 : 0.2) and 100 ml of pure CHC1 3 . The second extraction used 80 ml of MeOH:1 N HCl (1 : 1). Samples were spotted on 1% potassium oxalate treated thin layer chromatography (TLC) plates (Analtech, Newark, DE, USA) and developed in CHCl 3 :MeOH:N-H 4 OH:H 2 O (129 : 114 : 15 : 21). The highest migrating spots on the TLC plate, representing phosphatidylinositol-phosphate or PIP, were quantitated by densitometry on radiograph using Image Tool software (University of Texas Health Science Center, San Antonio, TX, USA). A lighter exposure radiograph was used for PIP quantitation in Figure 4c .
Cytoplasmic/nuclear extraction
Cells were grown, treated with drugs and stimulated as above. Nuclear and cytoplasmic proteins were puri®ed using NE-PER kit according to manufacturer's instructions (Pierce Biochemical, Rockford, IL, USA). Brie¯y, treated cells were harvested in cold PBS, then resuspended in CER I (106 packed cell volume). After thorough mixing and a 10 min incubation on ice, CER II was added (5.5% CER I volume), followed by more mixing. After 5 min centrifugation, supernatant (cytoplasmic fraction) was transferred. Insoluble fraction (pellet) was resuspended in NER I (50% CER I volume), mixed thoroughly four times every 10 min, and then centrifuged. Approximately equal percentages of the total nuclear and total cytoplasmic protein, after slight adjustments for protein concentration, were resolved by standard 10% SDS ± PAGE with 29 : 1 acrylamide:bis/acrylamide, so that all phospho species would migrate as a single band. FKHR immunoblotting was performed as above, and densitometry was performed using Alpha Imager 2000 (Alpha Innotech Corporation).
Immunofluorescence staining
Cells were grown to 70% con¯uence on 2-well chamber slides, serum starved, then stimulated as above. Cells were ®xed and stained as previously described (Glass and Kreisberg, 1993) . Brie¯y, cells were ®xed for 1 h at room temperature in three parts 100 mM Lysine HCl, 50 mM NaH 2 PO 4 .H 2 O, 10 mM Na-m-periodate, pH 7.4 and 1 part 8% paraformaldehyde clari®ed with NaOH. After three PBS washes, slides were blocked for 20 min in 1.5% donkey serum in TBS-saponin (25 mM Tris, 0.9% NaCl, 0.02% saponin), then blocked further in 5% nonfat dry milk in TBS-saponin at 378C. Slides were then incubated in primary FKHR antibody (1 : 50 dilution), or no primary antibody, in 5% milk-TBS-saponin, 0.05% Na Azide overnight at 48C in humidi®ed box. Slides were then washed four times for 15 min each in 5% milk-TBS-saponin-Na Azide and TBSsaponin, then incubated for 1 h at room temperature in the dark with¯uorescein-conjugated donkey anti-rabbit secondary antibody (25 mg/ml) in TBS-saponin. After three TBSsaponin washes and one TBS wash, slides were mounted and viewed under Zeiss epi¯uorescence photo microscope. Photographs of representative ®elds of view were taken.
